Flash FinanceUS
Market open S&P 5007,376.86+0.31% Nasdaq24,579.42+1.09% Dow 3051,285.73-0.46% Russell 20002,754.11+0.89% Nasdaq-10026,989.99+1.35% MidCap 4003,602.50+0.56% SmallCap 6001,673.98+0.05% VIX25.64-9.01% 10Y Yield4.86+0.45% Close of Nov 06, 2026
AI brief of an SEC Form 8-K · Viatris (VTRS)

Viatris appoints David Simmons, former Pfizer and PPD executive, to its Board

Neutral Impact 2 of 5 leadership Written later

Viatris expanded its Board from 14 to 15 members and appointed David Simmons as an independent director, effective immediately, with a term expiring at the 2025 annual meeting. The company has not yet named committee assignments, which it says it will disclose in a later amendment to this filing.

Key points

  • Board increased from 14 to 15 members; David Simmons appointed on August 4, 2025, with a term ending at the 2025 annual meeting
  • Simmons is the CEO of Caliber Holdings Corporation and previously served as Chairman and CEO of PPD, Inc.
  • He spent more than 15 years at Pfizer Inc., including overseeing its Established Products Unit
  • Simmons will receive compensation consistent with other non-employee directors, and the company has an indemnification agreement with him

The filing

CompanyViatris (VTRS)
Form8-K, current report
Filed with the SECAug 5, 2025, 7:30 AM ET
Accession number0001140361-25-028739

Items reported: 5.02 Director / Officer Change7.01 Regulation FD Disclosure

Read the filing on SEC.gov ↗

Written by AI on Nov 8, 2026, 12:42 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 05, 2025.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.